Skip to main content
SpringerLink
Log in

From FDG-PET to FDG-PET/CT Imaging

  • Chapter
Atlas of PET/CT Imaging in Oncology

Abstract

PET imaging with F-18 deoxyglucose (FDG) diagnoses, stages and restages most cancers with a high diagnostic accuracy.1,2 Treatment effects can be monitored early and with greater accuracy than with anatomic imaging modalities. FDG-PET provides prognostic information that is superior to that of conventional imaging.3–5 The high diagnostic and prognostic accuracy of PET has led to its acceptance as a standard oncological imaging tool.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002;53:89–112.

    Article  PubMed  CAS  Google Scholar 

  2. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(5 Suppl):lS–93S.

    Google Scholar 

  3. Jerusalem G, Beguin Y, Fasotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Whole-body positron emission tomograpohy using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94(2):429–433.

    PubMed  CAS  Google Scholar 

  4. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Prognostic value of positron emission tomoraphy (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 2001;19(2):414–419.

    PubMed  CAS  Google Scholar 

  5. Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, Valk PE, Czernin J. Whole-body 18F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med. 2002;43(3):325–329.

    PubMed  Google Scholar 

  6. Lardinois D, Weder W, Hany TE, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348(25):2500–2507.

    Article  PubMed  Google Scholar 

  7. Bar-Shalom R, Keidar Z, Guralnik L, Yefremov N, Sachs J, Israel O. Added value of fused PET/CT imaging with FDG in diagnostic imaging and management of cancer patients. J Nucl Med. 2002;43(5 Suppl):32P–33P.

    Google Scholar 

  8. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, Altman H, Keidar Z, Israel O. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44(8): 1200–1209.

    PubMed  Google Scholar 

  9. Antoch G, Freudenberg LS, Nemat AT, Beyer T, Bockisch A, Debatin JF. Preoperative staging of non-small cell lung cancer with dual-modality PET/CT imaging: a comparison with PET and CT. J Nucl Med. 2003;44(5 Suppl):172P.

    Google Scholar 

  10. Cohade C, Mourtzikos KA, Pannu HK, Leal JP, Bristow RE, Wahl RL. Direct comparison of PET and PET/CT in the detection of recurrent ovarian cancer. J Nucl Med. 2003;44(5 Suppl):129 P–130P.

    Google Scholar 

  11. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, Dahmen G, Bockisch A, Debatin JF, Ruehm SG. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003;290(24):3199–3206.

    Article  PubMed  CAS  Google Scholar 

  12. Warburg O, Posener K, Negelein E. VIII. The metabolism of cancer cells. Biochem Zeitschr. 1924;152:129–169.

    Google Scholar 

  13. Weber G. Enzymology of cancer cells (Part 1). N Engl J Med. 1977;296(9):486–492.

    Article  PubMed  CAS  Google Scholar 

  14. Weber G. Enzymology of cancer cells (Part 2). N Engl J Med. 1977;296(10):541–551.

    Article  PubMed  CAS  Google Scholar 

  15. Flier JS, Mueckler MJM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras and src oncogenes. Science. 1987;235(4795):1492–1495.

    Article  PubMed  CAS  Google Scholar 

  16. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med. 1975;16(3):210–224.

    PubMed  CAS  Google Scholar 

  17. Zhao S, Kuge Y, Tsukamoto E, Mochizuki T, Kato T, Hikosaka K, Nakada K, Hosokawa M, Kohanawa M, Tamaki N. Fluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loading. Nucl Med Commun. 2002;23(6):545–550.

    Article  PubMed  CAS  Google Scholar 

  18. Pedersen MW, Holm S, Lund EL, Hojgaard L, Kristjansen PE. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia. 2001;3(1):80–87.

    Article  PubMed  CAS  Google Scholar 

  19. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med. 1996;37(6): 1042–1047.

    PubMed  CAS  Google Scholar 

  20. Bos R van Der Hoeven JJ van Der Wall E van Der Groep P van Diest PJ Comans EF Joshi U Semenza GL Hoekstra OS Lammertsma AA Molthoff CF. Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;202379–387.

    Article  Google Scholar 

  21. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN, Hetzel M. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44(9): 1426–1431.

    PubMed  CAS  Google Scholar 

  22. Adams S, Baum R, Stuckensen T, Bitter K, Hör G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 1998;25(9): 1255–1260.

    Article  PubMed  CAS  Google Scholar 

  23. Rodriguez M, Rehn S, Ahlstrom H, Sundström C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin’s lymphoma. J Nucl Med. 1995;36(10): 1790–1796.

    PubMed  CAS  Google Scholar 

  24. Yap CS, Valk P, Ariannejad M, Seltzer MA, Phelps ME, Gambhir SS, Czernin J. FDG-PET influences the clinical management of lymphoma patients. J Nucl Med. 2000;41(5 Suppl):70P.

    Google Scholar 

  25. Safaei A, Figlin R, Hoh CK, Silverman DH, Seltzer M, Phelps ME, Czernin J. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol. 2002;57(1):56–62.

    PubMed  CAS  Google Scholar 

  26. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME, Gambhir SS, Hoh CK. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 1999; 162(4): 1322–1328.

    Article  PubMed  CAS  Google Scholar 

  27. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, Polascik TJ, Price DT. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61(1):110–117.

    PubMed  CAS  Google Scholar 

  28. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4(11): 1334–1336.

    Article  PubMed  CAS  Google Scholar 

  29. Tjuvajev JG, Chen SH, Joshi A, Joshi R, Guo ZS, Balatoni J, Ballon D, Koutcher J, Finn R, Woo SL, Blasberg RG. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res. 1999; 59(20): 5186–5193.

    PubMed  CAS  Google Scholar 

  30. Gambhir SS, Barrio JR, Wu L, Iyer M, Namavari M, Satyamurthy N, Bauer E, Parrish C, MacLaren DC, Borghei AR, Green LA, Sharfstein S, Berk AJ, Cherry SR, Phelps ME, Herschman HR. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med. 1998;39(11):2003–2011.

    PubMed  CAS  Google Scholar 

  31. MacLaren DC, Toyokuni T, Cherry SR, Barrio JR, Phelps ME, Herschman HR, Gambhir SS. PET imaging of transgene expression. Biol Psychiatry. 2000;48(5):337–348.

    Article  PubMed  CAS  Google Scholar 

  32. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA. 2000;97(16):9226–9233.

    Article  PubMed  CAS  Google Scholar 

  33. Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR. PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol. 1996;23(6):717–735.

    Article  PubMed  CAS  Google Scholar 

  34. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J, Maddahi J, Phelps ME. PET in oncology: will it replace the other modalities? Semin Nucl Med. 1997;27(2):94–106.

    Article  PubMed  CAS  Google Scholar 

  35. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41(8):1369–1379.

    PubMed  CAS  Google Scholar 

  36. Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA, Townsend DW. Combined PET/CT imaging in oncology: impact on patient management. Clin Positron Imaging. 2000;3(6):223–230.

    Article  PubMed  Google Scholar 

  37. Halpern B, Dahlbom M, Vranjesevic D, Ratib O, Schiepers C, Silverman DH, Waldherr C, Quon A, Czernin J. LSO-PET/CT whole body imaging in 7 minutes: is it feasible? J Nucl Med. 2003;44(5 Suppl):380P–381P.

    Google Scholar 

  38. Dahlbom M, Hoffman EJ, Hoh CK, Schiepers C, Rosenqvist G, Hawkins RA, Phelps ME. Whole-body positron emission tomography: part I. Methods and performance characteristics. J Nucl Med. 1992;33(6):1191–1199.

    PubMed  CAS  Google Scholar 

  39. Yap C, Quon A, Schiepers C, Dahlbom M, Ratib O, Czernin J. Additional Value of PET CT over PET for Cancer Staging and Lesion Localization. Radiology. 2003;229(Suppl):487.

    Google Scholar 

  40. Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, Bockisch A, Debatin JF, Freudenberg LS. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003;229:526–533.

    Article  PubMed  Google Scholar 

  41. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44(11):1797–1803.

    PubMed  Google Scholar 

  42. Osman MM, Cohade C, Nakamoto Y, Marshall LT, Leal JP, Wahl RL. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med. 2003;44(2):240–243.

    PubMed  Google Scholar 

  43. Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP, Gorges R, Nowrousian MR, Bockisch A, Debatin JF. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2003;In Press.

    Google Scholar 

Download references

Authors
  1. J. Czernin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Yap
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Czernin, J., Yap, C. (2004). From FDG-PET to FDG-PET/CT Imaging. In: Atlas of PET/CT Imaging in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18517-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18517-5_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62141-3

  • Online ISBN: 978-3-642-18517-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation